Skip to main content
. 2012 Apr 20;17(5):645–652. doi: 10.1634/theoncologist.2011-0448

Table 3.

Univariate and multivariate analyses of the prognostic role of serum PTH after 3 months of zoledronic acid therapy

graphic file with name onc00512-1045-t03.jpg

Patients had to have complete baseline and 3-mo PTH assessments and assessment of baseline prognostic factors. Patients entered the risk set at the time of study entry.

Abbreviations: BAP, bone-specific alkaline phosphatase; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NTX, N-telopeptide/creatinine ratio; PSA, prostate-specific antigen; PTH, parathyroid hormone; RR, relative risk.